Meta-analysis and cost-effectiveness of ductoscopy, duct excision surgery and MRI for the diagnosis and treatment of patients with pathological nipple discharge

M. D. Filipe1 · S. I. S. Patuleia2 · M. R. Vriens1 · P. J. van Diest2 · A. J. Witkamp1

Received: 9 November 2020 / Accepted: 4 January 2021 / Published online: 21 January 2021 © The Author(s) 2021

Abstract

Introduction Pathological nipple discharge (PND) is a common breast-related complaint for referral to a surgical breast clinic because of its association with breast cancer. The aim of this meta-analysis was to compare the diagnostic efficacy of magnetic resonance imaging (MRI) and ductoscopy in patients with PND. Additionally, we determined the most cost-efficient strategy for the treatment of PND and the detection of breast cancer in PND patient without radiological suspicion for malignancy.

Materials and methods PubMed and EMBASE were searched to collect the relevant literature from the inception of both diagnostic methods until January 27th 2020. The search yielded 815 original citations, of which 10 studies with 894 patients were finally included for analysis. Costs of ductoscopy, MRI and duct excision surgery were obtained from the UMC Utrecht as established in the year 2019. These costs included: medical personnel, overhead costs, material costs and sterilisation costs.

Results The meta-analysis showed no significant difference in sensitivity between ductoscopy (44%) and MRI (76%) for the detection of malignancy in patients with PND. However, ductoscopy (98%) had a statistically significantly higher specificity than MRI (84%). Individual costs were €1401.33, €822.13 and €6494.27 for ductoscopy, MRI and duct excision surgery, respectively. Full diagnostic strategy involving ductoscopy was on average €1670.97, while with MRI it was €2070.27.

Conclusion Patients undergoing MRI are more often (false) positive which more often leads to duct excision surgery referrals compared to ductoscopy. This makes ductoscopy significantly more cost-effective compared MRI in patients with PND without radiological suspicion for malignancy.

Introduction

Pathological nipple discharge (PND) is defined as unilateral, spontaneous and bloody or serous discharge, usually arising from a single duct orifice of the nipple. After pain and palpable lumps, PND is the third most common breast-related complaint [1] and it accounts for 3–5% of surgical breast clinic referrals [2–5] Even though it is considered a red-flag symptom for breast cancer, the most common causes of PND are benign, namely ductal ectasia and intraductal papillomas [6, 7].

Traditionally, patients suffering PND are offered major duct excision surgery to rule out malignancy [6, 8, 9], which occurs in only 5–8% [4, 10, 11]. This means that around 92–95% of these operations are performed for non-malignant causes. However, although invasive, the advantage of major duct excision is that it can also be helpful to treat PND itself.

Magnetic resonance imaging (MRI) has more recently shown to be a sensitive tool for the detection of malignancy in patients with PND. However, MRI has some
shortcomings, namely in the detection of small lesions and in differentiating benign from malignant masses [9, 12]. Therefore, the value of MRI is limited in patients with PND and core needle biopsy or surgical excision is still necessary when MRI shows a suspicious lesion [13, 14]. This not only leads to a longer diagnostic path but is also accompanied by accumulation of costs.

Ductoscopy is a minimally invasive micro-endoscopic technique providing real-time visualization of the milk ducts of the breast. This procedure is performed under local anaesthesia at the outpatient clinic and is currently used as a diagnostic tool in the work-up of women suffering from PND [15–22]. Ductoscopy has shown to be a useful tool in finding intraductal lesions causing PND (benign and malignant) [23–25]. Next to its diagnostic role, ductoscopy can potentially treat the actual cause of PND as well by mechanical removal [22, 26] or laser ablation [27] of intraductal lesions like papillomas. Therefore, ductoscopy has the ability to replace invasive surgical procedures in patients suffering from PND.

Besides their difference in diagnostic and therapeutic capabilities, major duct excision, MRI and ductoscopy also differ in costs. For example, although effective in the actual treatment of PND, the costs of major duct excision exceed those of MRI and ductoscopy together. So, better selection of patients that actually will benefit from duct excision is crucial to save costs and to save women from the undesirable side effects of surgery.

As the above shows, there is a need to establish the most cost-effective work-up for women presenting with PND. Therefore, the aim of our study was to compare the diagnostic performance for detecting breast cancer of ductoscopy and MRI in patients with PND in order to better select who is eligible for surgery. Additionally, we performed a cost-effectiveness analysis (CEA) for the diagnostic performance for detecting breast cancer of ductoscopy and MRI, followed by a CEA for the treatment of PND comparing major duct excision and ductoscopy.

Materials and methods

Meta-analysis

The systematic literature search on the diagnostic performance of ductoscopy and MRI was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for meta-analysis [28]. The PubMed and Embase databases were systematically searched for studies published until January 2020. The search strategy was performed on synonyms and medical subject heading (MESH) terms of pathological nipple discharge and the index tests (MRI and ductoscopy). Only articles that evaluated MRI and/or ductoscopy, reported original data and were written in English were selected. Full syntaxes are shown in Supplementary Appendix 1. After removal of duplicates, two authors (MF, SP) independently screened articles by title, abstract and full text. Any disagreement was solved through discussion to reach a consensus.

Selection of studies

Title/abstract screening was performed after removal of duplicates. Full texts were retrieved for studies that evaluated MRI and/or ductoscopy, reported original data and were written in English.

1. Participants: patients with PND without history of breast cancer or radiological suspicion of breast cancer.
2. Intervention: MRI and/or ductoscopy.
3. Comparator: all patients must have had definitive diagnosis of malignancy by the means of biopsy or histopathological analysis after surgery.
4. Outcome: diagnostic performance of ductoscopy and MRI for the detection of (pre)cancerous lesions.
5. Study characteristics: all studies accepted for publication written in English.

Studies were excluded from systematic review owing to the following reasons:

1. Not possible to determine sensitivity and specificity from the studies by means of true positive, true negative, false positive and true negative.
2. Studies in which none of the patients had histopathological confirmation of malignancy.
3. Case report, review and conference abstracts.

Risk of bias

The QUADAS-2 Tool was used to evaluate the quality of each eligible study [29]. The entire scale constituted four domains for the risk of bias: patient selection, index test, reference standard and flow and timing. Additionally, there were three domains for applicability concerns: patient selection, index test and reference standard. Each domain could be judged as any of the three levels, low risk, intermediate/unclear risk, or high risk of bias.

Additionally, funnel plots and Egger’s test were performed in order to see whether there was publication or small sampling bias [30].
**MRI**

MRI scans were classified according to the Breast Imaging Reporting and Data System (BI-RADS) reporting system [31]. BI-RADS I–III was considered benign and BI-RADS IV to VI were considered suspicious for malignancy or malignant.

**Cost-effectiveness analysis model**

Firstly, a CEA model was developed to capture the costs and effectiveness of ductoscopy, MRI and duct excision surgery. In this model, surgery was performed if ductoscopy or MRI was suspicious for breast cancer. Model outputs were represented in terms of effects of diagnostic success for the detection of breast cancer in patients with PND without suspicion for malignancy on ultrasound or mammography. A random sample of 10,000 patients per diagnostic method was generated with an incidence of 5% based on literature [10, 11]. Analysis was performed with 100 bootstraps.

Secondly, another CEA model was developed to determine the costs and effectiveness of ductoscopy in treating PND. Data were obtained from our previous clinical study [26]. Model outputs were represented in terms of effect of therapeutic success after ductoscopy and/or surgery in patients with PND without suspicion for malignancy on ultrasound or mammography.

A univariate sensitivity analysis was performed using as minimum and maximum values the lower and upper limits of the 95% confidence intervals for the sensitivity of ductoscopy and MRI. In addition, univariate sensitivity analysis was also performed with the different rates of successful ductoscopy according to the literature.

**Cost calculation**

Costs of ductoscopy comprised actual staff and equipment costs since ductoscopy is currently not (yet) covered by medical insurance in The Netherlands. The staff costs covered the surgeon performing the ductoscopy, two nurses (one scrub nurse and one circulating nurse) and overhead costs. Equipment costs consisted of ductoscopy materials (hardware and reusables), overhead costs, sterilisation costs of the 0.55 mm optic (LaDuScope T-flex; Polydiagnost) and the Polyshft 1.15-mm outer diameter, PD-DS-1015; Polydiagnost). The costs were incorporated in a decision model using probabilities of events and unit costs of ductoscopy and MRI [32]. The total costs of surgery were estimated based on average overall hospital costs, including surgical or nonsurgical charges of the UMC Utrecht. All costs are presented in Euros (€), according to the price quotes of 2019.

**Statistical analysis**

Firstly, sensitivity and specificity were calculated for ductoscopy and MRI with the 95% confidence interval (CI). After this, pooled estimates of sensitivity and specificity were calculated for ductoscopy and MRI using fixed-effects. Heterogeneity among studies was quantified by the I-square and tested using Cochran’s-Chi-square tests. Subsequently, the chance of a positive test (for MRI and ductoscopy), positive predictive value (PPV) and negative predictive value (NPV) were calculated from the pooled sensitivity, specificity and the prevalence of breast cancer.

Decision trees were modelled using TreeAge Pro V.2015 (TreeAge Software, Williamstown, Massachusetts, USA). All calculations were performed using RStudio 1.2.5001 (with R version: x64 3.6.3). Additionally, statistical packages meta, mada, metaphor and mvmeta were used for all computations and visualisations of the meta-analysis. Cost-effectiveness computations and visualisations were performed using ICEinfer package. Finally, other visualisation of plots was done using the ggplot2 package.

**Results**

**Meta-analysis**

A total of 815 citations of articles in English language were identified by the search and, after removing duplicates and screening on relevance, 73 potentially eligible articles were retrieved in full text (Fig. 1). Overall, 894 patients in 10 studies with PND underwent ductoscopy, MRI and/or duct excision surgery. Table 1 shows the details of the studies used in the analysis.

Figure 2 shows the diagnostic performance of ductoscopy and MRI. Ductoscopy had a pooled sensitivity of 44% (95% CI of 22–66%) for detection of breast cancer and a specificity of 98% (95% CI of 96–99%) for the detection of malignancy. Sensitivity and specificity of MRI were 76% (95% CI of 71–86%) and 84% (95% 80–88%), respectively. The prevalence of malignancy in patients with PND without radiological suspicion for malignancy was around 5% [10, 11]. Based on this prevalence, estimated PPV and NPV were 53.7% and 97.1% for ductoscopy, respectively. MRI had an estimated PPV of 20% and a NPV of 98.5%.

The result of the QUADAS-2 tool revealed that all the included studies were of sufficient quality. This was for both risks of bias domains and applicability domains (Supplementary Fig. 1). Additionally, this study showed symmetry of the effect, indicating no evidence for a small sample effect or publication bias in the subgroup analysis (Supplementary Fig. 2). P-values for Egger’s test for sensitivity and specificity were 0.0504 and 0.755, respectively.
Cost analysis

The input model (Table 2) was based on the data from the meta-analysis of this study, as well as other references and findings of the financial departments of the UMC Utrecht. The average costs of a ductoscopy procedure, a major duct excision operation and a breast MRI at the UMC Utrecht
in the year 2019 were €1401.33, €6494.27 and €822.13, respectively.

**Diagnostic cost-effectiveness analysis comparing ductoscopy to MRI**

Based on the diagnostic performance (sensitivity, specificity, PPV and NPV) calculated earlier, Supplementary Fig. 3 shows the CEA of the diagnostic performance of ductoscopy, duct excision surgery and MRI for the detection of cancer in patients with PND with negative conventional radiological findings.

The chance of positive findings at ductoscopy (including unsuccessful ductoscopy procedures) was 4.1%, of which 53.7% were true positive. Consequently, the chance of negative findings at ductoscopy was 95.9% of which 97.1% was true negative. Hence, based on diagnostic performances and costs, the average cost of ductoscopy to diagnose (pre) cancerous lesions, and subsequent surgery when positive, would be €1670.97. The diagnostic accuracy of ductoscopy was 95.3%.

MRI was positive in 19.0% of the cases, of which 20.0% were true positive. Therefore, the chance of a negative MRI was 81.0% of which 98.5% was true negative. Furthermore,
the average estimated cost using MRI to diagnose (pre)cancerous lesions, and subsequent surgery when positive, in PND patients would be €2070.27. This based on the fact that 19% of patients with PND without radiological suspicion for malignancy are estimated to have a positive MRI and therefore referred for surgery. This results in a sum of the costs of MRI (€822.13) and the in 19% of the cases surgery (€6494.27). The diagnostic accuracy of MRI was 83.6%. Exact calculations can be found in Supplementary Fig. 3. The current study showed that ductoscopy was more cost-effective for the detection of malignancy in patient with PND compared to MRI, regardless of the margin of error of the sensitivity (95% CI). Sensitivity analysis determining the different cost-effectiveness based on the 95% CI sensitivity of ductoscopy and MRI can be found in Supplementary Table 1.

**Therapeutic cost-effectiveness analysis comparing ductoscopy to surgery**

In our previous study 215 patients underwent a ductoscopy procedure. The therapeutic success rate was defined as total relief of PND for at least three months (median follow-up was 14.1 months), regardless of the findings during the ductoscopy itself. The technical success rate of ductoscopy itself was 70.2% (i.e. the procedure could be fully accomplished and sufficient inspection of the ductal tree was possible). A total of 60 patients (27.9%) were operated, for different reasons, in addition to ductoscopy; ductoscopy itself technically failed (N = 24), suspicious findings (N = 8) or the PND did not stop (N = 42). In 60.3% of the technically successful ductoscopy procedures (i.e. inspection of the ductal tree was possible) the PND stopped, of which 7.7% were subsequently operated due to suspicious findings. Consequently, in 39.7% of technically successful ductoscopy procedures the PND did not stop of which 48.3% underwent surgery [26].

Thereby, the effectivity of ductoscopy was 51.2% (percentage of patients that no longer suffered PND) and the average total cost of a patient with PND undergoing a therapeutic strategy with ductoscopy was €3208.89. This cost is based on the sum of the cost for ductoscopy (€1401.33) and the fact that 48.3% of patients that underwent ductoscopy also underwent subsequent duct excision surgery (€6494.27). Exact calculations can be found in the Supplementary Fig. 4. The current study showed that ductoscopy was more cost-effective for the treatment of PND compared to duct excision surgery, regardless cannulation rates reported by the literature. Sensitivity analysis determining the different cost-effectiveness based on the cannulation of ductoscopy according to the literature can be found in Supplementary Table 2.

**Discussion**

In this study, a meta-analysis was performed on the diagnostic performances of ductoscopy and MRI for the detection of (pre)cancerous lesion in patients with PND without radiological suspicion for malignancy. This study also shows the results of a CEA comparing ductoscopy to MRI in this group of patients for the detection of malignancy and also their capability to select patients for major duct excision. Finally, we performed a CEA comparing ductoscopy to major duct excision for the therapeutic effect in resolving PND in these patients.

For the meta-analysis, 10 studies were finally selected, which together included a total of 894 patients suffering from PND. We compared ductoscopy to MRI in terms of sensitivity and specificity. Pooled sensitivity and specificity of ductoscopy were 44% and 98%, respectively. MRI showed a pooled sensitivity of 76% and 84%, respectively. There were no statistically significant differences in sensitivity, but specificity was statistically significantly higher for ductoscopy.

In recent years, MRI has been used more often for the detection of breast cancer in patients with PND. Based on our meta-analysis, MRI has a high sensitivity for the detection of breast cancer in this group. However, due to a relatively low specificity, histopathological assessment through surgery or biopsy remains necessary to determine whether the lesion is benign-or-not [13, 14]. MRI is also increasingly used in cases of PND when mammography and ultrasound are negative [8, 12, 33, 34]. The current study clarifies that MRI has a higher sensitivity (although not significant) but shows at the same time a statistically significantly lower specificity in comparison to ductoscopy for the detection of breast cancer in patients with PND. Contrast enhanced MRI appears to be a promising imaging method for the detection of breast cancer in this group of patients [35–37]. However, contrast enhanced MRI studies in PND patients are scarce and include only few patients for which reason they were not included in our meta-analysis [35–37].

Over the last few decades, ductoscopy has been gaining ground for detection of lesions causing PND [38–43]. The meta-analysis performed in this study shows that ductoscopy has a similar (not significant) sensitivity (44 vs 86%) but a significantly higher (84 vs. 98%) specificity in comparison with MRI. However, since the prevalence of (pre)cancerous lesions is only around 5% in patients suffering PND without radiological signs of malignancy, specificity is a more useful tool to determine diagnostic performance. This is also reflected by the fact that our study shows that the diagnostic accuracy of ductoscopy (95.3%) is significantly higher compared with MRI (83.6%). Therefore, it is
safe to conclude that ductoscopy seems to be a more useful tool to determine which patients are eligible for (duct excision) surgery. This is in line with previous studies that showed that ductoscopy successfully reduces the need for surgery in patients with PND [26, 44]. Additionally, since intraductal extractions are nowadays possible with the basket extraction device and pilot studies with laser ablation have been done [26, 45], ductoscopy also has a therapeutic potential in the treatment of PND itself [22], making it an even more attractive modality.

In our study we also show that ductoscopy is more beneficial (11.9%) and less costly (€399.30) compared with MRI for the proper selection of PND patients for surgery. This can be explained by the specificity of MRI and ductoscopy. With a malignancy prevalence of 5%, the significantly higher specificity of ductoscopy ensures that only 4.1% of ductoscopy procedures are positive (regardless whether it is true positive or false positive). This means that only 4.1% of patients will undergo surgery when ductoscopy is used. However, since specificity of MRI is significantly lower (84%), despite the fact that sensitivity is higher, the chance of a positive MRI is 19%. This means that 19% of patients with PND without radiological suspicion will undergo surgery. Consequently, when a MRI is performed, chances of a PND patient undergoing surgery is almost 5 times higher. Therefore, even though a single MRI is less costly than a ductoscopy (€822.13 vs. €1401.33, respectively), this analysis shows that it would still be considerably less expensive to use ductoscopy as a strategy in determining the need for surgery in this patient population. Multivariate sensitivity analysis taking the uncertainties of the sensitivities for the detection of malignancy in patients with PND with negative conventional imaging of ductoscopy and MRI into account showed no significant changes to these conclusions.

As mentioned above, ductoscopy (unlike MRI) also has a potential therapeutic effect on the PND itself. This results in a further decrease in the number of major duct excisions needed. Based on the clinical data from our previous published study we showed that in over half (51.7%) of patients undergoing (attempted) ductoscopy the PND actually stopped and only 27.9% of women suffering PND finally needs surgery after ductoscopy [26].

Our study also has some limitations. First, the diagnostic section was modelled, based on pooled diagnostic performances of ductoscopy and MRI. However, there was an unexplained difference in the prevalence of malignancy between ductoscopy (4.5%) and MRI (19%) studies. This might explain the high heterogeneity for specificity in both ductoscopy and MRI. Since there is a consensus that the malignancy rate in patients with PND without radiological signs of malignancy is around 5% [14, 24], the current study parted from that premise and did not include prevalence in the sensitivity analysis. Second, in the included studies there are different definitions of a technically successful ductoscopy. This study defined successful ductoscopy as being able to visualise the ductal tree. However, other studies defined successful ductoscopy as being able to cannulate the ductal tree, regardless of being able to visualise-or-not. We performed a sensitivity analysis for this uncertainty but this did not change the conclusions. Thirdly, since most intraductal lesions causing PND are directly behind the nipple, biopsy is often not possible and surgery is recommended [46, 47]. For this reason, costs of biopsy were not taken into account in this study. Fourthly, all costs were obtained from only one hospital, since the UMC Utrecht is the only hospital in The Netherlands performing ductoscopy. Although costs for medical procedures might differ from one hospital to another, it does not seem very likely that the ratio between these costs within one hospital will vary much. Therefore, the effect on our analysis is probably limited. At last, there are currently no studies describing the quality of life of patients with PND undergoing MRI, ductoscopy or duct excision surgery. For that reason, quality of adjusted life analysis was not used in this study.

To conclude, this study is the first to directly compare the diagnostic performance of ductoscopy and MRI in patients with PND without radiological signs of malignancy. This study shows that ductoscopy has a significantly higher diagnostic accuracy in this patient population. This makes ductoscopy less costly and a more effective diagnostic tool in comparison with MRI to determine which patients finally require surgery to rule out malignancy. Furthermore, this CEA showed that, while ductoscopy is not as effective in treating PND as duct excision surgery, it is much less costly.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Hussain AN, Policarpio C, Vincent MT (2006) Evaluating nipple discharge. Obstet Gynecol Surv 61(4):278–83
2. Seltzer MH (2004) Breast complaints, biopsies, and cancer correlated with age in 10,000 consecutive new surgical referrals. Breast J 10(2):111–7
3. Santen RJ, Mansel R (2005) Benign breast disorders. N Engl J Med 353(3):275–85
4. King TA, Carter KM, Bolton JS, Fuhrman GM, et al (2000) A simple approach to nipple discharge. Am Surg. 66(10):960–6. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L30777959

5. Sajadi-Ernazarafo KR, Sugumar K, Adigun R (2020) Breast nipple discharge. StatPearls, Treasure Island

6. Alcock C, Layer GT (2010) Predicting occult malignancy in nipple discharge. ANZ J Surg 80(9):646–9. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L359537186

7. Albrecht C, Thele F, Grunwald S, Kohlmann T, Hegenscheid K, Utpatel K et al (2013) Nipple discharge: role of ductoscopy in comparison with standard diagnostic tests. Onkologie 36(1–2):12–6

8. Bahl M, Baker JA, Greenup RA, Ghate SV (2015) Diagnostic value of ultrasound in female patients with nipple discharge. AJR Am J Roentgenol 205(1):203–8

9. Sanders LM, Daigle M (2016) The rightful role of MRI after negative conventional imaging in the management of bloody nipple discharge. Breast J 22(2):209–12

10. Galvin R, Joyce D, Downey E, Boland F, Fahey T, Hill AK (2014) Development and validation of a clinical prediction rule to identify suspected breast cancer: a prospective cohort study. BMC Cancer 14(1):743

11. Lesetedi C, Rayne S, Kruger D, Benn CA (2017) Indicators of breast cancer in patients undergoing microdochectomy for a pathological nipple discharge in a middle-income country. J Surg Res 220:336–40

12. van Gelder L, Bisschops RH, Menke-Pluymers MB, Westendorf PJ, Plaisier PW (2015) Magnetic resonance imaging in patients with unilateral bloody nipple discharge; useful when conventional diagnostics are negative? World J Surg 39(1):184–8

13. Lee SJ, Trikha S, Moy L, Baron P, di Florio RM et al (2017) ACR appropriateness criteria (IR) evaluation of nipple discharge. J Am Coll Radiol 14(5S):S138-53

14. de Paula IB (2017) Campos AM. Breast imaging in patients with nipple discharge, Radiol Bras

15. Yamamoto D, Shoji T, Hajiimma H, Gondo H, et al (2001) A utility of ductography and fiberoptic ductoscopy for patients with nipple discharge. Breast Cancer Res Treat 70(2):103–8

16. Yamamoto D, Ueda S, Senzaki H, Shoji T, Hajiimma H, Gondo H et al (2001) New diagnostic approach to intracystic lesions of the breast by fiberoptic ductoscopy. Anticancer Res 21(6A):4113–6

17. Okazaki A, Okazaki M, Asaishi K, Satoh H, Watanabe Y, Mikami H et al (1991) Fiberoptic ductoscopy of the breast: a new diagnostic procedure for nipple discharge. Jpn J Clin Oncol 21(3):188–93

18. Matsunaga T, Ohta D, Misaka T, Hosokawa K, Fujii M, Kaise H et al (2001) Mammary ductoscopy for diagnosis and treatment of intraductal lesions of the breast. Breast Cancer 8(3):213–21

19. Grunwald S, Heyer H, Paepeke S, Schwesinger G, Schimming A, Hahn M et al (2007) Diagnostic value of ductoscopy in the diagnosis of nipple discharge and intraductal proliferations in comparison to standard methods. Onkologie 30(5):243–8

20. Han Y, Li J, Han S, Jia S, Zhang Y, Zhang W (2017) Diagnostic value of endoscopic appearance during ductoscopy in patients with pathological nipple discharge. BMC Cancer 17(1):300–3

21. Kamali S, Bender O, Kamali GH, Aydin MT, Karatepe O, Yuney E (2014) Diagnostic and therapeutic value of ductoscopy in nipple discharge and intraductal proliferations compared with standard methods. Breast Cancer 21(2):154–61

22. Waaijer L, van Diest PJ, Verkooijen HM, Dijkstra NE, van der Pol CC, Borel Rinkes IH et al (2015) Interventional ductoscopy in patients with pathological nipple discharge. Br J Surg 102(13):1639–48

23. Jacobs VR, Kiechle M, Plattner B, Fischer T, Paepke S (2005) Breast ductoscopy with a 0.55-mm mini-endoscope for direct visualization of intraductal lesions. J Minim Invasive Gynecol 12(4):359–64

24. Waaijer L, Simons JM, Borel Rinkes IH, van Diest PJ, Verkooijen HM, Witkamp AJ (2016) Systematic review and meta-analysis of the diagnostic accuracy of ductoscopy in patients with pathological nipple discharge. Br J Surg 103(6):632–43

25. Makita M, Akiyama F, Gomi N, Iwase T (2016) Mammary ductoscopy and watchful follow-up substitute microdochectomy in patients with bloody nipple discharge. Breast Cancer (2012):242–51

26. Filipe MD, Waaijer L, van der Pol CC, van Diest P, Witkamp AJ (2020) Interventional ductoscopy as an alternative for major duct excision or microdochectomy in women suffering pathological nipple discharge: a single centre experience. Clin Breast Cancer 20(3):e334–e343

27. de Boor T, Waaijer L, van Diest PJ, Witkamp AJ (2018). Ex vivo feasibility study of endoscopic intraductal laser ablation of the breast. Lasers Surg Med 50(2):137–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28900682

28. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–84

29. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–36

30. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–34

31. Rao AA, Feneis J, Lalonde C, Ojeda-Fournier H (2016) A pictorial review of changes in the BI-RADS fifth edition. Radiographics 36(3):623–39

32. Kooerkamp BG, Hunink MG, Stijnen T, Hammitt JK, Kuntz KM, Weinstein MC (2007) Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making 27(2):101–11

33. Zacharioudakis K, Kontoulis T, Vella JX, Zhao J, Ramakrishnan R, Cunningham DA et al (2019) Can we see what is invisible? The role of MRI in the evaluation and management of patients with pathological nipple discharge. Breast Cancer Res Treat 178(1):115–20

34. Bahl M, Baker JA, Greenup RA, Ghate SV (2015) Evaluation of prophylactic nipple discharge: what is the added diagnostic value of MRI? Ann Surg Oncol 22(Suppl 3):S435-41

35. Nicholson BT, Harvey JA, Patrie JT, Mugler JP (2015) 3D-MR Ductography and contrast-enhanced MR mammography in patients with suspicious nipple discharge. A feasibility study. Breast J 21(4):352–62

36. Lorenzo M, Zucchi C, Landa V, Girometti R, Bazzocchi M (2011) Magnetic resonance imaging in patients with nipple discharge: should we recommend it? Eur Radiol. 21(5):899–907

37. Orel SG, Dougherty CS, Reynolds C, Czernecki BJ, Siegelman ES, Schnall MD (2000) MR imaging in patients with nipple discharge: initial experience. Radiology 216(1):248–54

38. Zielinski J, Jaworski R, Irga-Jaworska N, Pikula M, Hunerbein M (2015) Ex-vivo feasibility study of endoscopic intraductal laser ablation of the breast. Lasers Surg Med 47(9):845–53

39. Vaughan A, Crowe JP, Brainard J, Dawson A, Kim J, Dietz JR (2009) Mammary ductoscopy and ducal washings for the evaluation of patients with pathologic nipple discharge. Breast J 15(3):254–60
40. Bender O, Balci FL, Yuney E, Akbulut H (2009) Scarless endoscopic papillomectomy of the breast. Onkologie 32(3):94–8
41. Denewer A, El-Etribi K, Nada N, El-Metwally M (2008) The role and limitations of mammary ductoscope in management of pathologic nipple discharge. Breast J 14(5):442–9
42. Gui G, Agusti A, Twelves D, Tang S, Kabir M, Montgomery C et al (2018) INTEND II randomized clinical trial of intraoperative duct endoscopy in pathological nipple discharge. Br J Surg 105(12):1583–90
43. Zielinski J, Jaworski R, Irga-Jaworska N, Haponiuk I, Jaskiewicz J (2015) The significance of ductoscopy of mammary ducts in the diagnostics of breast neoplasms. Videosurgery Other Minimvasive Tech [Wideochirurgia i inne Tech maloinwazyjne] 10(1):79–86
44. Chang YK, Chen CTH, Wang M, Yang Y, Mark B, Zheng A, et al (2020) Could ductoscopy alleviate the need of microdochectomy in pathological nipple discharge? Breast Cancer. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32008216
45. Waaijer L, Filipe MD, Simons J, van der Pol CC, de Boorder T, van Diest PJ et al (2020) Detection of breast cancer precursor lesions by autofluorescence ductoscopy. Breast Cancer 28:119–129
46. Chesbro AL, Chikarmane SA, Ritner JA, Birdwell RL, Giess CS (2017) Troubleshooting to overcome technical challenges in image-guided breast biopsy. RadioGraphics 37(3):705–18
47. Bick U, Trimboli RM, Athanasiou A, Balleyguier C, Baltzer PAT, Bernathova M et al (2020) Image-guided breast biopsy and localisation: recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights Imaging 11(1):12
48. Morrogh M, Morris EA, Liberman L, Borgen PI, King TA (2007) The predictive value of ductography and magnetic resonance imaging in the management of nipple discharge. Ann Surg Oncol 14(12):3369–77
49. Bahl M, Gadd MA, Lehman CD (2017) JOURNAL CLUB: diagnostic utility of MRI after negative or inconclusive mammography for the evaluation of pathologic nipple discharge. AJR Am J Roentgenol 209(6):1404–10

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.